Log In
Print
BCIQ
Print
Print this Print this
 

olokizumab (CDP6038)

  Manage Alerts
Collapse Summary General Information
Company UCB Group
DescriptionHumanized mAb against IL-6
Molecular Target Interleukin-6 (IL-6)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA); Treat rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)
Regulatory Designation

Partner

R-Pharm CJSC


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today